Number of Employees
Marlboro, Next, L&M, Virginia Slims and Sampoerna
Philip Morris Singapore Pte. Ltd. is the leading tobacco company in Singapore which distributes and sells Philip Morris International (PMI) brands, including Marlboro, Next, L&M, Virginia Slims and Sampoerna. The company’s direct sales and distribution operation was established in 1998, but PMI’s brands have been on the market in Singapore for many years.
Philip Morris International Research Laboratories Pte. Ltd. is one of the two Philip Morris International research and development (R&D) facilities that is dedicated to the development and scientific assessment of products with the potential to reduce individual risk and population harm in comparison to smoking combustible cigarettes. Our R&D headquarter is based on Neuchâtel, Switzerland. For more information on PMI research activities, please visit www.pmiscience.com.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.